AgingResearch.NewsJoin free

Insilico Medicine

CompanyUnited States

Insilico Medicine develops 31 assets, the furthest in phase 3 (rentosertib in idiopathic pulmonary fibrosis). Mostly small molecule acting on TNIK, EGLN1 and EGLN2; based in the United States.

31
Assets
Furthest stage
Phase 3
Raised
US$729.8m
1
Trial
0
Signals

Pipeline

31

  • rentosertib

    Selective TNIK inhibitor that curbs inflammation, myofibroblast activation and fibrotic remodelling; a senomorphic in cells

    Phase 3, Small molecule, Cellular senescence, TNIK, idiopathic pulmonary fibrosis

  • garutadustat

    Inhibits PHD1/2, stabilizing HIFα to promote epithelial barrier healing and reduce proinflammatory cytokine expression.

    Phase 2, Small molecule, EGLN1, EGLN2, inflammatory bowel disease, ulcerative colitis

  • ISM3412

    Oral MAT2A inhibitor, synthetically lethal in cancers that have lost MTAP

    Phase 1, Small molecule, MAT2A, MTAP-deleted solid tumours

28 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms9
  • Trials1
  • Funding rounds and grants7
  • People24
  • Signals20
  • Similar companies6

Papers

Intelligence